According to Yahoo!Finance, “Babcock & Wilcox Enterprises, Inc. provides fossil and renewable power generation and environmental equipment for the power and industrial markets worldwide.”
The Study of Failure
“On 2 December 2006, Pfizer was faced with a devastating finding: the biggest prospect in their near-term pipeline--the lipid-modulating agent torcetrapib--had raised the risk of death and heart problems in the pivotal ILLUMINATE trial. The company promptly halted development of its cholesteryl ester transfer protein (CETP) inhibitor, into which it had already invested US$800 million, and watched its share price plummet (Learning lessons from Pfizer's $800 million failure." Nature Reviews Drug Discovery, vol. 10, no. 3, 2011, p. 163+. Academic OneFile, http://link.galegroup.com/apps/doc/A251088305/AONE?u=sfpl_main&sid=AONE&xid=c6cd54f5. Accessed 10 Dec. 2018.).”